Sonova (OTCMKTS:SONVY) Upgraded to “Equal Weight” at Morgan Stanley

Sonova (OTCMKTS:SONVY) was upgraded by Morgan Stanley from an “underweight” rating to an “equal weight” rating in a report issued on Tuesday.

Several other research analysts have also commented on the company. BNP Paribas Exane raised Sonova from a “strong sell” rating to a “strong-buy” rating in a research report on Tuesday, March 10th. Jefferies Financial Group lowered Sonova from a “hold” rating to a “moderate sell” rating in a research note on Wednesday, March 18th. Finally, Citigroup reissued a “sell” rating on shares of Sonova in a research report on Wednesday, May 13th. Two investment analysts have rated the stock with a Strong Buy rating, one has given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy”.

Sonova Stock Performance

Sonova stock opened at $47.90 on Tuesday. The business has a fifty day moving average of $48.54 and a two-hundred day moving average of $49.94. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.43 and a current ratio of 1.75. Sonova has a twelve month low of $42.26 and a twelve month high of $61.09.

About Sonova

Sonova AG (OTCMKTS:SONVY) is a Switzerland-based provider of hearing care solutions, headquartered in Stäfa. The company designs, develops, manufactures and distributes a range of audiological products and related services aimed at improving hearing and communication for people with hearing loss. Its portfolio spans behind-the-ear and in-the-ear hearing instruments, wireless accessories and software solutions that enable connectivity with consumer devices and audiological fittings.

Sonova markets its products under several well-known brands, including Phonak and Unitron for hearing aids, and it is also associated with Advanced Bionics for cochlear implant systems.